Abbott Message To Investors About Medicare Rx: Don't Believe The Hype
This article was originally published in The Pink Sheet Daily
It will take as much as a decade to determine what the impact of the new Medicare legislation is on the pharmaceutical industry, Abbott CEO Miles White says. The trade-off between price and volume will be "essentially neutral."
You may also be interested in...
Past support for so-called ‘march in’ rights is a red flag for biopharma innovators, but after two days of confirmation hearings, industry can be somewhat reassured.
It remains uncertain whether Acting Commissioner Woodcock will be nominated for the post. Regardless, the drug center she has run for most of three decades is going to have to adjust to new management.
President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.